Literature DB >> 30714270

Prodrome in relapsing-remitting and primary progressive multiple sclerosis.

J M A Wijnands1, F Zhu1, E Kingwell1, Y Zhao1, C Evans2, J D Fisk3, R A Marrie4, H Tremlett1.   

Abstract

BACKGROUND AND
PURPOSE: The multiple sclerosis prodrome remains poorly understood. We aimed to examine the prodrome in people with relapsing remitting multiple sclerosis at onset (RMS) and primary progressive multiple sclerosis (PPMS).
METHODS: We conducted a matched cohort study using clinical and linked health administrative data in two Canadian provinces. We identified people with RMS, PPMS and age- sex- and geographically-matched population controls, and compared the number of physician encounters (total number, per International Classification of Diseases chapter, and per physician speciality) in the five years before symptom onset. Negative binomial regression models were sex, age, socioeconomic status and calendar year adjusted.
RESULTS: We identified 1887 RMS, 171 PPMS cases, and 9837 matched population controls. No difference existed in the total number of encounters in the five years before index between RMS and PPMS, or between the phenotypes and their respective controls. Compared to RMS cases, PPMS cases had more nervous system-related encounters (adjusted rate ratio, 3.00; 95% confidence interval, 1.06-8.49) and fewer encounters with dermatologists (adjusted rate ratio 0.53; 95% confidence interval, 0.30-0.96).
CONCLUSION: Findings suggest that people with RMS and PPMS may both experience a prodrome, although aspects may differ.
© 2019 EAN.

Entities:  

Keywords:  healthcare utilization; multiple sclerosis; population-based data; prodrome

Mesh:

Year:  2019        PMID: 30714270     DOI: 10.1111/ene.13925

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  5 in total

1.  Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis.

Authors:  Kjetil Bjornevik; Kassandra L Munger; Marianna Cortese; Christian Barro; Brian C Healy; David W Niebuhr; Ann I Scher; Jens Kuhle; Alberto Ascherio
Journal:  JAMA Neurol       Date:  2020-01-01       Impact factor: 18.302

2.  Prodromal symptoms might vary between multiple sclerosis subtypes.

Authors:  Rebecca Kelsey
Journal:  Nat Rev Neurol       Date:  2019-04       Impact factor: 42.937

3.  The Multiple Sclerosis Prodrome: Evidence to Action.

Authors:  Helen Tremlett; Kassandra L Munger; Naila Makhani
Journal:  Front Neurol       Date:  2022-01-31       Impact factor: 4.086

Review 4.  The multiple sclerosis prodrome.

Authors:  Naila Makhani; Helen Tremlett
Journal:  Nat Rev Neurol       Date:  2021-06-21       Impact factor: 42.937

5.  Onset Symptom Clusters in Multiple Sclerosis: Characteristics, Comorbidities, and Risk Factors.

Authors:  Vladeta Ajdacic-Gross; Nina Steinemann; Gábor Horváth; Stephanie Rodgers; Marco Kaufmann; Yanhua Xu; Christian P Kamm; Jürg Kesselring; Zina-Mary Manjaly; Chiara Zecca; Pasquale Calabrese; Milo A Puhan; Viktor von Wyl
Journal:  Front Neurol       Date:  2021-07-06       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.